Market Overview

UPDATE: Canaccord Genuity Reiterates Hold Rating, Raises PT on AEterna Zentaris

Share:
Related AEZS
Earnings Scheduled For March 17, 2015
Aeterna Zentaris: Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin in Prostate Cancer Published in Clinical Cancer Research

In a report published Monday, Canaccord Genuity reiterated its Hold rating on AEterna Zentaris (NASDAQ: AEZS), and slightly raised its price target from $2.25 to $2.50.

Canaccord Genuity noted, “We view the recently granted Special Protocol Assessment for AEZS-108 as an incremental positive for AEterna Zentaris, as it modestly reduces regulatory risk, in our view. The upcoming Phase III pivotal study is set to enroll 500 patients and will compare AEZS-108 against doxorubicin; the primary endpoint of the trial is Overall Survival. While we recognize AEterna Zentaris' deep late-stage pipeline, beyond the interim analysis from the high-risk study of perifosine, we do not anticipate many meaningful catalysts for the stock in the near-term.”

AEterna Zentaris closed on Friday at $2.47.

Latest Ratings for AEZS

DateFirmActionFromTo
Apr 2015HC WainwrightUpgradesNeutralBuy
Jul 2014HC WainwrightInitiates Coverage onBuy
Jul 2013Euro PacificInitiates Coverage onHold

View More Analyst Ratings for AEZS
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Price Target Analyst Ratings

 

Related Articles (AEZS)

Around the Web, We're Loving...